• Publications
  • Influence
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
TLDR
Findings suggest that gain-of-function mutations in DDR2 are important oncogenic events and are amenable to therapy with dasatinib, and provide a rationale for designing clinical trials with the FDA-approved drug d asatinib in patients with lung SCCs.
Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers
TLDR
A gene-expression signature of the hypoxia response, derived from studies of cultured mammary and renal tubular epithelial cells, showed coordinated variation in several human cancers, and was a strong predictor of clinical outcomes in breast and ovarian cancers.
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
TLDR
Dabrafenib plus trametinib represents a new therapy with clinically meaningful antitumour activity and a manageable safety profile in patients with previously untreated BRAFV600E-mutant NSCLC.
Frequent mutations in chromatin-remodeling genes in pulmonary carcinoids
TLDR
Pulmonary carcinoids are not early progenitor lesions of the highly aggressive lung neuroendocrine tumors but arise through independent cellular mechanisms, suggesting that inactivation of chromatin remodeling genes is sufficient to drive transformation in pulmonary carcinoids.
Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling
TLDR
It is demonstrated that by means of a pathway-based modeling methodology (PARADIGM) integrating different layers of molecular data from whole-tumor samples, this work can stratify immune signatures that predict patient survival.
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
TLDR
Alectinib significantly improved systemic and CNS efficacy versus chemotherapy for crizotinib-pretreated ALK-positive NSCLC patients, with a favorable safety profile.
Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis
TLDR
This work demonstrates that changes in the epigenome occur early in the neoplastic progression, provides evidence for the possible utilization of DNA methylation-based markers of progression in the clinic, and highlights the importance of epigenetic changes in carcinogenesis.
Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer
TLDR
Stromal CD8+ TIL density has independent prognostic impact in resected NSCLC, adds prognosticimpact within each pathologic stage (pStage), and is a good candidate marker for establishing a TNM-Immunoscore.
Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors
TLDR
It is shown LCNECs represent a distinct transcriptional subgroup among lung cancers and comprise two molecular subgroups, type I (TP53 and STK11/KEAP1 alterations) and type II ( TP53 and RB1 inactivation).
Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression
TLDR
Analysis of a set of 419 functionally relevant genes involved in synthesis, degradation and binding of N‐linked and O‐linked glycans, Lewis antigens, glycosaminoglycans and glycosphingolipids indicated that synthesis, degraded and adhesion mediated by glycans may be altered drastically in mammary carcinomas.
...
1
2
3
4
5
...